Alivus Life Sciences Share Price
1370.00-48.80 (-3.44%)
+46.16% past 1 Year
Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system
Corporate filings & documents
Announcements
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meetings
1 week agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meetings
1 week agoEnclosed please find herewith Press Release with respect to Acquisition.
2 weeks agoEnclosed please find herewith Press Release with respect to Acquisition.
2 weeks agoEnclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR) 2015 with respect to acquisition.
2 weeks agoEnclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR) 2015 with respect to acquisition.
2 weeks agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting
3 weeks agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting
3 weeks agoPlease find enclosed herewith Newspaper Advertisement of Notice of 15th Annual General Meeting and E-Voting information.
3 weeks agoPlease find enclosed herewith Newspaper Advertisement of Notice of 15th Annual General Meeting and E-Voting information.
3 weeks agoPlease find enclosed herewith the Business Responsibility & Sustainability Report for FY 2025-26
3 weeks agoPlease find enclosed herewith the Business Responsibility & Sustainability Report for FY 2025-26
3 weeks agoPlease find enclosed herewith Integrated Annual Report FY 2025-26 under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 weeks agoPlease find enclosed herewith Integrated Annual Report FY 2025-26 under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 weeks agoPlease find attached herewith Notice convening the 15th Annual General Meeting.
3 weeks agoPlease find attached herewith Notice convening the 15th Annual General Meeting.
3 weeks agoEnclosed please find herewith details of investor meet.
3 weeks agoPlease find attached herewith details of Analyst/Investor meet.
4 weeks agoPlease find attached herewith details of Analyst/Investor meet.
4 weeks agoPlease find attached herewith transcript of Earnings call held on 31 July 2026.
4 weeks agoPlease find attached herewith transcript of Earnings call held on 31 July 2026.
4 weeks agoNewspaper Advertisement for 15th Annual General Meeting (AGM)
4 weeks agoNewspaper Advertisement for 15th Annual General Meeting (AGM)
4 weeks agoIntimation of Record date for Dividend.
4 weeks agoIntimation of Record date for Dividend.
4 weeks agoIntimation of 15th Annual General Meeting and Record date.
4 weeks agoIntimation of 15th Annual General Meeting and Record date.
4 weeks agoWe hereby confirm that we have uploaded audio recording of the Q1 FY2027 Earnings Call held on July 31 2026 on the website of the Company.
1 month agoWe hereby confirm that we have uploaded audio recording of the Q1 FY2027 Earnings Call held on July 31 2026 on the website of the Company.
1 month agoEnclosed please find herewith intimation with respect to allotment of equity shares under Employee Stock Options Scheme 2021
1 month agoEnclosed please find herewith intimation with respect to allotment of equity shares under Employee Stock Options Scheme 2021
1 month agoEnclosed please find herewith Investors Presentation for Q1 FY 2026-27.
1 month agoEnclosed please find herewith Investors Presentation for Q1 FY 2026-27.
1 month agoEnclosed please find herewith Press Release of the Company for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith Press Release of the Company for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith unaudited financial results for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith unaudited financial results for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith unaudited financial results for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith unaudited financial results for the first quarter ended June 30 2026.
1 month agoEnclosed please find herewith the details of Earnings Call slated for Friday July 31 2026 from 8:30 a.m. to 9:30 a.m. (IST) for your information and record.
1 month agoEnclosed please find herewith the details of Earnings Call slated for Friday July 31 2026 from 8:30 a.m. to 9:30 a.m. (IST) for your information and record.
1 month agoIntimation of closure of Trading Window from 1st July 2026 to 1st August 2026 (both days inclusive) for the purpose of approval of unaudited financial results for the quarter ended 30th June 2026.
1 month agoIntimation of closure of Trading Window from 1st July 2026 to 1st August 2026 (both days inclusive) for the purpose of approval of unaudited financial results for the quarter ended 30th June 2026.
1 month agoAlivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.
1 month agoAlivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.
1 month agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Institutional Investor Meeting - Plant Visit
2 months agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Institutional Investor Meeting - Plant Visit
2 months agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Analyst / Institutional Investor Meeting.
2 months agoDisclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting
3 months agoPlease find enclosed herewith transcript of Earnings Call held on 15th May 2026 which is also made available on the website of the Company.
3 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
Jul 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
Oct 2024
ConcallPresentation
Oct 2024
ConcallPresentation
Jul 2024
ConcallPresentation
Jul 2024
ConcallPresentation
Apr 2024
Jan 2024
ConcallPresentation
Jan 2024
ConcallPresentation
Oct 2023
Jul 2023
Apr 2023
ConcallPresentation
Apr 2023
ConcallPresentation
Jan 2023
Oct 2022
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Apr 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-09-01
Dividend
5.0
2025-09-01
Dividend
5.0
Company details
Registered office
Plot No. 170-172 Chandramouli Industrial Estate Mohol Bazarpeth Solapur Maharashtra PIN: 413213 Tel No: 02189 234456/234246 Fax No: NULL Email: [email protected] Internet: www.alivus.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Rudalf Corriea, Company Secretary & Compliance Officer
Hiren K Patel, Chairman
Yasir Rawjee, Managing Director & Chief Executive Officer
Kaushikbhai N Patel, Non Executive Independent Director
Manju Agarwal, Non Executive Independent Director
TL Easwar, Non Executive Independent Director
Savan Godiawala, Non Executive Independent Director
Vinod Naik, Whole Time Director - Technical Operations
Details
BSE 543322
NSE ALIVUS
ISIN INE03Q201024